PURPOSE: To demonstrate clinicopathologic characteristics of gastric cancer patients who underwent noncurative gastrectomy with long-term survival. METHODS: We retrospectively reviewed 202 advanced gastric cancer patients who underwent noncurative gastrectomy. RESULTS: The long-term survivors who survived for more than 3 years comprised four of 65 patients with a residual tumor in the peritoneum, one of 50 patients with a residual tumor from lymph node metastasis, three of 41 patients positive for the resected margin (M-factor) and 17 of 153 patients with free intraperitoneal cancer cells (Cy-factor). Multivariate analysis indicated that independent indicators affecting survival were lymph node metastasis and peritoneal metastasis in patients with the Cy-factor and histology in patients with the M-factor. CONCLUSIONS: Long-term survival can only be expected in patients with the Cy-factor who have neither macroscopic peritoneal metastasis nor lymph node metastasis or in patients with the M-factor who have a well-differentiated tumor.
PURPOSE: To demonstrate clinicopathologic characteristics of gastric cancerpatients who underwent noncurative gastrectomy with long-term survival. METHODS: We retrospectively reviewed 202 advanced gastric cancerpatients who underwent noncurative gastrectomy. RESULTS: The long-term survivors who survived for more than 3 years comprised four of 65 patients with a residual tumor in the peritoneum, one of 50 patients with a residual tumor from lymph node metastasis, three of 41 patients positive for the resected margin (M-factor) and 17 of 153 patients with free intraperitoneal cancer cells (Cy-factor). Multivariate analysis indicated that independent indicators affecting survival were lymph node metastasis and peritoneal metastasis in patients with the Cy-factor and histology in patients with the M-factor. CONCLUSIONS: Long-term survival can only be expected in patients with the Cy-factor who have neither macroscopic peritoneal metastasis nor lymph node metastasis or in patients with the M-factor who have a well-differentiated tumor.
Authors: E Bando; Y Yonemura; Y Takeshita; K Taniguchi; T Yasui; Y Yoshimitsu; S Fushida; T Fujimura; G Nishimura; K Miwa Journal: Am J Surg Date: 1999-09 Impact factor: 2.565
Authors: K Hanazaki; Y Mochizuki; T Machida; S Yokoyama; H Sodeyama; Y Sode; M Wakabayashi; N Kawamura; T Miyazaki Journal: Hepatogastroenterology Date: 1999 Mar-Apr